Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue.
Sign Up to like & getrecommendations! Published in 2022 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2021.7239
Abstract: Importance Trastuzumab deruxtecan (T-DXd) has shown efficacy in patients with breast cancer with ERBB2 immunohistochemistry (IHC) scores of 1+ or 2+ but not 0 as read in central pathology laboratories. The drug is currently being… read more here.
Keywords: ihc; erbb2; breast cancer; low erbb2 ... See more keywords